Porwal Auto Components Limited received listing approval from the Bombay Stock Exchange on August 19, 2026, for equity shares issued through a preferential allotment. The company secured permission to list 17,54,384 equity shares with a face value of ₹10 each, allotted to non-promoter investors at an issue price of ₹57 per share. This price includes a premium of ₹47 per share.

Transaction Details

The preferential issue involves distinctive numbers ranging from 15100001 to 16854384. The allotment was made to both promoters and non-promoters under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Compliance and Next Steps

The BSE approval letter mandates compliance with Regulation 167 of the SEBI (ICDR) Regulations. The company must file the shareholding pattern in XBRL mode under Regulation 31(1)(c) of the SEBI LODR Regulations if there is a change exceeding two percent of the total paid-up share capital.

Trading approval for these shares is contingent upon several additional filings:

• Listing approval from the National Stock Exchange of India Ltd., if applicable.
• Confirmation letters from NSDL or CDSL regarding the crediting of shares to beneficiary accounts and admission of capital to the depository system.
• Confirmation letters from depositories concerning the lock-in of pre-preferential holdings, if applicable.

As per Schedule XIX of the ICDR Regulations and SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023, Porwal Auto Components must apply for trading approval within seven working days of receiving listing approval. Failure to comply may attract fines as specified in the same circular.

Porwal Auto Components Limited disclosed that its promoter group, led by Mrs. Pramila Jain, acquired 3,94,735 warrants on July 09, 2026, increasing their holding in the company. This acquisition, representing 2.29% of the fully diluted share capital, was executed through a preferential allotment. The capital infusion follows approvals from shareholders and BSE Limited, raising the company's paid-up equity share capital to ₹16,85,43,840.

The warrants were allotted at an issue price of ₹57.00 per warrant, aggregating to a total issue size of ₹2,24,99,895. The company received ₹56,24,973.75 as an upfront payment, which constitutes 25% of the warrant issue price. These instruments are valid for 18 months from the date of allotment and are convertible into one fully paid-up equity share of ₹10 each upon payment of the balance consideration of ₹42.75 per warrant.

The total equity share capital post-allotment stands at ₹16,85,43,840, divided into 1,68,54,384 equity shares. The fully diluted share capital, including the warrants, amounts to ₹17,24,91,190, consisting of 1,72,49,119 equity shares. The board also approved obtaining an International Securities Identification Number (ISIN) for these convertible warrants.

Breakdown of Promoter Acquisition

*Includes shares held by other Persons Acting in Concert (PACs).

Key Details of the Issue

• Warrant Upfront Payment: 25% of issue price (₹14.25 per warrant).
• Warrant Balance Payment: ₹42.75 per warrant due at conversion.
• Post-Allotment Paid-up Capital: ₹16,85,43,840 divided into 1,68,54,384 equity shares.
• Total Diluted Capital: ₹17,24,91,190 divided into 1,72,49,119 equity shares.